乳酸双歧杆菌Probio-M8可改善绝经后骨质疏松症患者的骨代谢，可能是通过调节肠道微生物群来实现的。
Bifidobacterium lactis Probio-M8 improves bone metabolism in patients with postmenopausal osteoporosis, possibly by modulating the gut microbiota.
作者信息
Zhao Feiyan, Guo Zhenguo, Kwok Lai-Yu, Zhao Zhixin, Wang Kexin, Li Yalin, Sun Zhihong, Zhao Jianmin, Zhang Heping
机构信息
Inner Mongolia Key Laboratory of Dairy Biotechnology and Engineering, Key Laboratory of Dairy Products Processing, Ministry of Agriculture and Rural Affairs, Key Laboratory of Dairy Biotechnology and Engineering, Ministry of Education, Inner Mongolia Agricultural University, Hohhot, 010018, Inner Mongolia, China.
Department of Orthopaedics, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, 010018, Inner Mongolia, China.
出版信息
Eur J Nutr. 2023 Mar;62(2):965-976. doi: 10.1007/s00394-022-03042-3. Epub 2022 Nov 5.
PURPOSE
Postmenopausal osteoporosis (PMO) is usually managed by conventional drug treatment. However, prolonged use of these drugs cause side effects. Gut microbiota may be a potential target for treatment of PMO. This work was a three-month intervention trial aiming to evaluate the added effect of probiotics as adjunctive treatment for PMO.
METHODS
Forty patients with PMO were randomized into probiotic (n = 20; received Bifidobacterium animalis subsp. lactis Probio-M8 [Probio-M8], calcium, calcitriol) and placebo (n = 20; received placebo material, calcium, calcitriol) groups. The bone mineral density of patients was measured at month 0 (0 M; baseline) and month 3 (3 M; after three-month intervention). Blood and fecal samples were collected 0 M and 3 M. Only 15 and 12 patients from Probio-M8 and placebo groups, respectively, provided complete fecal samples for gut microbiota analysis.
RESULTS
No significant change was observed in the bone mineral density of patients at 3 M. Co-administering Probio-M8 improved the bone metabolism, reflected by an increased vitamin D3 level and decreased PTH and procalcitonin levels in serum at 3 M. Fecal metagenomic analysis revealed modest changes in the gut microbiome in both groups at 3 M. Interestingly, Probio-M8 co-administration affected the gut microbial interactive correlation network, particularly the short-chain fatty acid-producing bacteria. Probio-M8 co-administration significantly increased genes encoding some carbohydrate metabolism pathways (including ABC transporters, the phosphotransferase system, and fructose and mannose metabolism) and a choline-phosphate cytidylyltransferase.
CONCLUSIONS
Co-administering Probio-M8 with conventional drugs/supplements was more efficacious than conventional drugs/supplements alone in managing PMO. Our study shed insights into the beneficial mechanism of probiotic adjunctive treatment.
REGISTRATION NUMBER OF CLINICAL TRIAL
Chinese Clinical Trial Registry (identifier number: ChiCTR1800019268).
目的
绝经后骨质疏松症（PMO）通常采用传统药物治疗。然而，长期使用这些药物会产生副作用。肠道微生物群可能是治疗PMO的一个潜在靶点。本研究是一项为期三个月的干预试验，旨在评估益生菌作为PMO辅助治疗的附加效果。
方法
40例PMO患者被随机分为益生菌组（n = 20；接受动物双歧杆菌乳亚种Probio-M8 [Probio-M8]、钙、骨化三醇）和安慰剂组（n = 20；接受安慰剂、钙、骨化三醇）。在第0个月（0M；基线）和第3个月（3M；三个月干预后）测量患者的骨密度。在0M和3M采集血液和粪便样本。Probio-M8组和安慰剂组分别只有15例和12例患者提供了用于肠道微生物群分析的完整粪便样本。
结果
在3M时，患者的骨密度未观察到显著变化。联合使用Probio-M8改善了骨代谢，这体现在3M时血清中维生素D3水平升高、甲状旁腺激素（PTH）和降钙素原水平降低。粪便宏基因组分析显示，两组在3M时肠道微生物群有适度变化。有趣的是，联合使用Probio-M8影响了肠道微生物相互作用相关网络，特别是产短链脂肪酸的细菌。联合使用Probio-M8显著增加了一些碳水化合物代谢途径（包括ABC转运蛋白、磷酸转移酶系统以及果糖和甘露糖代谢）和胆碱磷酸胞苷转移酶的编码基因。
结论
在治疗PMO方面，联合使用Probio-M8与传统药物/补充剂比单独使用传统药物/补充剂更有效。我们的研究揭示了益生菌辅助治疗的有益机制。
临床试验注册号
中国临床试验注册中心（标识符编号：ChiCTR1800019268）。
Zotero 插件